{
    "address1": "210 East Grand Avenue",
    "city": "South San Francisco",
    "state": "CA",
    "zip": "94080",
    "country": "United States",
    "phone": "650 457 2700",
    "website": "https://www.allogene.com",
    "industry": "Biotechnology",
    "industryDisp": "Biotechnology",
    "sector": "Healthcare",
    "sectorDisp": "Healthcare",
    "longBusinessSummary": "Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.",
    "fullTimeEmployees": 359,
    "companyOfficers": [
        {
            "maxAge": 1,
            "name": "Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.",
            "age": 73,
            "title": "Co-Founder & Exec. Chairman",
            "yearBorn": 1949,
            "fiscalYear": 2022,
            "totalPay": 714248,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Dr. David D. Chang M.D., Ph.D.",
            "age": 62,
            "title": "Co-Founder, Pres, CEO & Director",
            "yearBorn": 1960,
            "fiscalYear": 2022,
            "totalPay": 1100480,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Joshua A. Kazam",
            "age": 45,
            "title": "Co-Founder & Director",
            "yearBorn": 1977,
            "fiscalYear": 2022,
            "totalPay": 711000,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Yinlin  Chen",
            "title": "Sr. VP of Fin.",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Timothy L. Moore Ph.D.",
            "age": 61,
            "title": "Exec. VP & Chief Technical Officer",
            "yearBorn": 1961,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Barbra  Sasu",
            "title": "Chief Scientific Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Stephen  Cheng",
            "title": "Chief Information Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Mr. Earl M. Douglas Esq.",
            "age": 59,
            "title": "Gen. Counsel & Compliance Officer",
            "yearBorn": 1963,
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Christine  Cassiano",
            "title": "Chief Communications Officer",
            "exercisedValue": 0,
            "unexercisedValue": 0
        },
        {
            "maxAge": 1,
            "name": "Ms. Susan R. Lundeen",
            "age": 56,
            "title": "Chief People Officer",
            "yearBorn": 1966,
            "exercisedValue": 0,
            "unexercisedValue": 0
        }
    ],
    "auditRisk": 2,
    "boardRisk": 9,
    "compensationRisk": 10,
    "shareHolderRightsRisk": 8,
    "overallRisk": 9,
    "governanceEpochDate": 1693526400,
    "compensationAsOfEpochDate": 1672444800,
    "maxAge": 86400,
    "priceHint": 4,
    "previousClose": 4.0,
    "open": 4.0,
    "dayLow": 3.9192,
    "dayHigh": 4.115,
    "regularMarketPreviousClose": 4.0,
    "regularMarketOpen": 4.0,
    "regularMarketDayLow": 3.9192,
    "regularMarketDayHigh": 4.115,
    "payoutRatio": 0.0,
    "beta": 0.769417,
    "forwardPE": -1.8545454,
    "volume": 1536496,
    "regularMarketVolume": 1536496,
    "averageVolume": 2656833,
    "averageVolume10days": 1567400,
    "averageDailyVolume10Day": 1567400,
    "bid": 0.0,
    "ask": 0.0,
    "bidSize": 2200,
    "askSize": 800,
    "marketCap": 683914048,
    "fiftyTwoWeekLow": 3.7,
    "fiftyTwoWeekHigh": 15.31,
    "priceToSalesTrailing12Months": 3562.0522,
    "fiftyDayAverage": 4.5966,
    "twoHundredDayAverage": 5.9066,
    "trailingAnnualDividendRate": 0.0,
    "trailingAnnualDividendYield": 0.0,
    "currency": "USD",
    "enterpriseValue": 290155584,
    "profitMargins": 0.0,
    "floatShares": 105695128,
    "sharesOutstanding": 167626000,
    "sharesShort": 32768529,
    "sharesShortPriorMonth": 41258839,
    "sharesShortPreviousMonthDate": 1689292800,
    "dateShortInterest": 1692057600,
    "sharesPercentSharesOut": 0.19549999,
    "heldPercentInsiders": 0.29435,
    "heldPercentInstitutions": 0.98585,
    "shortRatio": 15.22,
    "shortPercentOfFloat": 0.2883,
    "impliedSharesOutstanding": 167626000,
    "bookValue": 3.727,
    "priceToBook": 1.0947143,
    "lastFiscalYearEnd": 1672444800,
    "nextFiscalYearEnd": 1703980800,
    "mostRecentQuarter": 1688083200,
    "netIncomeToCommon": -354688000,
    "trailingEps": -2.42,
    "forwardEps": -2.2,
    "pegRatio": -1.79,
    "enterpriseToRevenue": 1511.227,
    "enterpriseToEbitda": -0.843,
    "52WeekChange": -0.71862066,
    "SandP52WeekChange": 0.08443928,
    "exchange": "NMS",
    "quoteType": "EQUITY",
    "symbol": "ALLO",
    "underlyingSymbol": "ALLO",
    "shortName": "Allogene Therapeutics, Inc.",
    "longName": "Allogene Therapeutics, Inc.",
    "firstTradeDateEpochUtc": 1539264600,
    "timeZoneFullName": "America/New_York",
    "timeZoneShortName": "EDT",
    "uuid": "074a6d28-e148-3d16-a323-524e6da42340",
    "messageBoardId": "finmb_558022022",
    "gmtOffSetMilliseconds": -14400000,
    "currentPrice": 4.08,
    "targetHighPrice": 35.0,
    "targetLowPrice": 5.0,
    "targetMeanPrice": 16.93,
    "targetMedianPrice": 15.0,
    "recommendationMean": 1.9,
    "recommendationKey": "buy",
    "numberOfAnalystOpinions": 15,
    "totalCash": 491961984,
    "totalCashPerShare": 2.935,
    "ebitda": -344372992,
    "totalDebt": 98202000,
    "quickRatio": 9.01,
    "currentRatio": 9.176,
    "totalRevenue": 192000,
    "debtToEquity": 15.765,
    "revenuePerShare": 0.001,
    "returnOnAssets": -0.26071,
    "returnOnEquity": -0.49785998,
    "grossProfits": 243000,
    "freeCashflow": -118261872,
    "operatingCashflow": -238247008,
    "revenueGrowth": -0.488,
    "grossMargins": 0.0,
    "ebitdaMargins": 0.0,
    "operatingMargins": -1866.9324,
    "financialCurrency": "USD",
    "trailingPegRatio": null,
    "parent_etfs": [
        "GNOM"
    ]
}